People using SGLT2 inhibitors are nearly 40 per cent less at risk of developing acute kidney injury or kidney disease compared to individuals not taking the medication, latest evidence identifies.
A new study has found that SGLT2 inhibitors can prevent the development of renal complications, despite the diabetes status and kidney function of the person prescribed the drug.
During the investigation, a team of researchers looked at the MEDLINE and Embase databases to analyse different SGLT2 inhibitor trials.
The 13 trials under review included 90,413 adults living with diabetes and 15,605 adults living without diabetes.
SGLT2 inhibitors reduced the risk of kidney disease progression by 37 per cent in all of the participants, according to the study.
The findings also show that the FDA-approved drug reduced the risk of active injury, cardiovascular death and hospitalisation for heart failure by more than 20 per cent.
The results noted: “SGLT2 inhibitors also reduced the risk of cardiovascular death but did not significantly reduce the risk of non-cardiovascular death.
““For all outcomes, results were broadly similar irrespective of trial mean baseline estimated glomerular filtration rate.”
They added: “Based on estimates of absolute effects, the absolute benefits of SGLT2 inhibition outweighed any serious hazards of ketoacidosis or amputation.”
The full research study can be found here.